Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole.

W Wolfgang Fleischhacker1

  • 1Department of Biological Psychiatry, Medical University Innsbruck, Austria.

Expert Opinion on Pharmacotherapy
|October 4, 2005
PubMed
Summary
This summary is machine-generated.

Aripiprazole, a novel antipsychotic, demonstrates superior efficacy over placebo for schizophrenia and bipolar disorder. It is generally well-tolerated, with manageable side effects like akathisia and somnolence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.

Psychiatry research·2026
Same author

Identifying Transdiagnostic Predictors of Depression across Psychoses: Informing Stratified Antidepressant Treatments.

Psychotherapy and psychosomatics·2026
Same author

Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence-based treatment predictions in diverse psychosis populations.

Psychiatry and clinical neurosciences·2025
Same author

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

CNS drugs·2025
Same author

AI-based prediction of depression symptomatology in first-episode psychosis patients: insights from the EUFEST and RAISE-ETP clinical trials.

Psychological medicine·2025
Same author

Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN.

Schizophrenia (Heidelberg, Germany)·2024
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Aripiprazole is a novel chemical entity with a distinct pharmacological profile.
  • It exhibits strong affinities for dopamine receptors and intermediate affinities for serotonin, adrenergic, and histamine receptors.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and tolerability of aripiprazole.
  • To understand the functional basis of its therapeutic effects through receptor interactions.

Main Methods:

  • Clinical trials assessing antipsychotic and antimanic properties in schizophrenia and bipolar disorder patients.
  • Dose-ranging studies (10-30 mg/day) and longer-term trials for maintenance and relapse prevention.

Main Results:

Related Experiment Videos

  • Aripiprazole showed antipsychotic and antimanic properties superior to placebo.
  • Longer-term trials confirmed maintenance of effects and relapse prevention in schizophrenia.
  • The drug is generally well-tolerated, with common side effects including akathisia, somnolence, and nausea, often dose-dependent and transient.

    • Conclusions:

    • Aripiprazole represents a significant addition to the antipsychotic drug spectrum.
    • Its unique partial agonism at D2 dopamine and 5HT1A serotonin receptors, and 5HT2 antagonism, underpin its efficacy.
    • Further research in diverse indications and confirmation of clinical trial results are warranted.